The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Astellas to Place Greater Importance on China Business: Executive Katayanagi
March 28, 2012
- Nippon Shinyaku Submits NDA for Alcohol Abstinence Aid Acamprosate
March 28, 2012
- Ajinomoto, Takeda Submit Domestic Application for Once-Monthly Risedronate
March 28, 2012
- Anticancer Agents Set to Become Top Therapeutic Category in 2012: IMS Japan
March 28, 2012
- Nichi-Iko Provides Wholesalers with Monthly Supply Volume of Epadel Generic
March 27, 2012
- Epadel Generic in Short Supply at Sawai Pharmaceutical Due to Promotional Measures
March 26, 2012
- Daiichi Sankyo Submits NDA for Denosumab for Osteoporosis in Japan
March 26, 2012
- Daiichi Sankyo to Develop Unapproved Narcotic Analgesic in Japan
March 26, 2012
- Suzuken Establishes New Company Specializing in Rare Diseases
March 26, 2012
- Nexium No. 1 in MR Call Frequency in HP Market in February: Rep Track Survey
March 26, 2012
- Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 3
March 26, 2012
- Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 4
March 26, 2012
- Bayer Yakuhin to Initiate Drug Use-Result Survey on 10,000 Patients for Xarelto
March 23, 2012
- Shionogi Submits PIIa Clinical Trial Application for OncoTherapy’s AMD Vaccine
March 23, 2012
- Ajinomoto Pharmaceuticals to Market Gastritis/Ulcer Treatment Marzulene from July
March 23, 2012
- Astellas Vice Deputy Chairman Ishii Says Company R&D Strategy Focused on Personalized Medicine
March 22, 2012
- India’s Ministry of Commerce and Industry Kicks Off “Brand India Pharma” Campaign
March 22, 2012
- BD Japan Seeking Further Partnerships with Japanese Companies: Pres. Harris
March 22, 2012
- MTPC, Novartis Revise Package Insert of Imusera/Gilenya in Response to Overseas Death
March 22, 2012
- MSD, BIKEN Sign Domestic Marketing Agreement for 3 Flu Vaccines
March 22, 2012
ページ
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…